John A Rousou1. 1. Division of Cardiac Surgery, Baystate Medical Center, Springfield, Massachusetts 01107, USA. jrousou@comcast.net
Abstract
BACKGROUND: Fibrin sealants are used for hemostasis and tissue adherence. AIM OF STUDY: This systematic review summarizes published clinical data for fibrin sealant use in cardiovascular surgery. METHODS: A literature search for the following terms was conducted using PubMed and EMBASE: (TISSEEL or Tissucol or Beriplast P or Evicel or Quixil or Crosseal or Reliseal or Fibringluraas or Bolheal or Tachosil or Vivostat or Vitagel or Artiss or "fibrin glue" or "fibrin sealant" or "fibrin tissue adhesive") and (cardiac or cardiovascular or vascular or heart or coronary or surgery). Case reports and series were excluded; although reports of controlled trials were preferred, uncontrolled trial data were also considered. RESULTS: Clinical trials and chart review analyses of fibrin sealants were identified and summarized. Although clinical trial data were available for other agents, the majority of published studies examined TISSEEL. Overall, TISSEEL and other fibrin sealants showed improvements over standard of care or control groups for a variety of predefined endpoints. Safety findings are also summarized. CONCLUSIONS: Data from these studies showed that fibrin sealants were well tolerated and provided effective hemostasis in a range of cardiac and aortic surgeries.
BACKGROUND: Fibrin sealants are used for hemostasis and tissue adherence. AIM OF STUDY: This systematic review summarizes published clinical data for fibrin sealant use in cardiovascular surgery. METHODS: A literature search for the following terms was conducted using PubMed and EMBASE: (TISSEEL or Tissucol or Beriplast P or Evicel or Quixil or Crosseal or Reliseal or Fibringluraas or Bolheal or Tachosil or Vivostat or Vitagel or Artiss or "fibrin glue" or "fibrin sealant" or "fibrin tissue adhesive") and (cardiac or cardiovascular or vascular or heart or coronary or surgery). Case reports and series were excluded; although reports of controlled trials were preferred, uncontrolled trial data were also considered. RESULTS: Clinical trials and chart review analyses of fibrin sealants were identified and summarized. Although clinical trial data were available for other agents, the majority of published studies examined TISSEEL. Overall, TISSEEL and other fibrin sealants showed improvements over standard of care or control groups for a variety of predefined endpoints. Safety findings are also summarized. CONCLUSIONS: Data from these studies showed that fibrin sealants were well tolerated and provided effective hemostasis in a range of cardiac and aortic surgeries.
Authors: Nicholas A Kurniawan; Bart E Vos; Andreas Biebricher; Gijs J L Wuite; Erwin J G Peterman; Gijsje H Koenderink Journal: Biophys J Date: 2016-09-06 Impact factor: 4.033
Authors: Francisco Javier Pérez Lara; Jose Manuel Hernández González; Arminda Ferrer Berges; Isabel Navarro Gallego; Herman Oehling de Los Reyes; Horacio Oliva Muñoz Journal: J Gastrointest Surg Date: 2018-09-05 Impact factor: 3.452
Authors: Katherine J Kearney; Nikoletta Pechlivani; Rhodri King; Christian Tiede; Fladia Phoenix; Ramsah Cheah; Fraser L Macrae; Katie J Simmons; Iain W Manfield; Kerrie A Smith; Benjamin E J Spurgeon; Khalid M Naseem; Robert A S Ariens; Michael J McPherson; Darren C Tomlinson; Ramzi A Ajjan Journal: Blood Date: 2018-12-13 Impact factor: 22.113